“…Depsipeptid metastatik meme kanseri hücrelerinde insan P53 geninin ifadesini artırırken ancak tümörlü olmayan komşu hücrelerinde etkisi yoktur 90 . 4 saatlik beklemeden sonra güvenli bir şekilde tatbik edilebilir 91 .…”
“…Sistin olmayan bir disülfid köprüsü içeren Chromobacterium violaceum'dan izole edilmiş bir bisiklik peptidtir ve kültüre edilmiş tümör hücrelerinde lipoplex türevi genlerin ifadesini arttırır. Depsipeptid metastatik meme kanseri hücrelerinde insan P53 geninin ifadesini artırırken ancak tümörlü olmayan komşu hücrelerinde etkisi yoktur 90 . 4 saatlik beklemeden sonra güvenli bir şekilde tatbik edilebilir 91 .…”
Cancer progression can be controlled by both genetic and epigenetic alterations. Only epigenetic alterations are reversible unlike the genetic alterations. This can be a important advantage to suggest that epigenetic modifications should be preferred in therapy applications. DNA methyltransferases and histone deacetylases have become the primary targets for studies in epigenetic therapy. The US Food and Drug Administration approved some DNA methylation inhibitors and histone deacetylation inhibitors as anti-cancer drugs. Therefore, the uses of epigenetic targets are believed to have great potential as a lasting favorable approach in treating breast cancer.
“…Depsipeptid metastatik meme kanseri hücrelerinde insan P53 geninin ifadesini artırırken ancak tümörlü olmayan komşu hücrelerinde etkisi yoktur 90 . 4 saatlik beklemeden sonra güvenli bir şekilde tatbik edilebilir 91 .…”
“…Sistin olmayan bir disülfid köprüsü içeren Chromobacterium violaceum'dan izole edilmiş bir bisiklik peptidtir ve kültüre edilmiş tümör hücrelerinde lipoplex türevi genlerin ifadesini arttırır. Depsipeptid metastatik meme kanseri hücrelerinde insan P53 geninin ifadesini artırırken ancak tümörlü olmayan komşu hücrelerinde etkisi yoktur 90 . 4 saatlik beklemeden sonra güvenli bir şekilde tatbik edilebilir 91 .…”
Cancer progression can be controlled by both genetic and epigenetic alterations. Only epigenetic alterations are reversible unlike the genetic alterations. This can be a important advantage to suggest that epigenetic modifications should be preferred in therapy applications. DNA methyltransferases and histone deacetylases have become the primary targets for studies in epigenetic therapy. The US Food and Drug Administration approved some DNA methylation inhibitors and histone deacetylation inhibitors as anti-cancer drugs. Therefore, the uses of epigenetic targets are believed to have great potential as a lasting favorable approach in treating breast cancer.
“…In addition, this improvement was blocked by treatment with free haloperidol and no differences in transgene expression were obtained for targeted and non-targeted LPS in CHO cells, which express low sigma receptor levels [46]. Subsequently, the group of Leaf Huang proposed the use of anisamide as a sigma-1 receptor ligand [47]. Incorporation of anisamide into their lipid-based carrier improved siRNA delivery by 4-fold in B16F10 murine melanoma cells.…”
Section: Small Molecules Improve Na Internalization By Target Cellsmentioning
confidence: 99%
“…From this point onwards, the transgene expression is furthermore subjected to epigenetic regulation mechanisms [74]. Histone hyperacetylation is typically associated with gene expression by facilitating access of transcription factors and RNA polymerase to the unwound DNA [47,75]. In contrast, histone deacetylation and methylation of a pDNA promoter region silences transgene expression [76].…”
Section: Small Molecules Boost Transgene Expressionmentioning
“…Depsipeptide increases the expression of the human p53 gene in metastatic breast cancer cells, but not in adjacent normal cells [59]. It can be safely administered when given as a 4-hour infusion [60].…”
Both genetic and epigenetic alterations can control the progression of cancer. Genetic alterations are impossible to reverse, while epigenetic alterations are reversible. This advantage suggests that epigenetic modifications should be preferred in therapy applications. DNA methyltransferases and histone deacetylases have become the primary targets for studies in epigenetic therapy. Some DNA methylation inhibitors and histone deacetylation inhibitors are approved by the US Food and Drug Administration as anti-cancer drugs. Therefore, the uses of epigenetic targets are believed to have great potential as a lasting favorable approach in treating breast cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.